We evaluated a combination therapy co-targeting EGFR and PI3K in models of basal-like breast cancer in vitro and demonstrate synergistic anti-cancer effects that shrinks tumors in vivo, with greater efficacy than either monotherapy. The gene discussed is EGFR; the disease is cancer.